1cP-LSD
1cP-LSD, or 1-CPA-LSD, also known as 1-cyclopropanoyl-LSD or as Curie, is a psychedelic drug of the lysergamide family and an acylated derivative of lysergic acid diethylamide which has been sold as a designer drug. It is a prodrug of LSD.1cP-LSD has been used in the form of blotter tabs containing 100μg 1cP-LSD free base and pellets containing 150μg 1cP-LSD hemitartrate. Its dose is said to be 100 to 200μg and it has comparable potency to 1P-LSD and 1B-LSD. Its duration has been said to be 5 to 10hours.Interactions
Pharmacology
Pharmacodynamics
1cP-LSD is a prodrug of LSD. It has been found to produce psychedelic-like effects, specifically the head-twitch response, in rodents with similar potency as 1P-LSD.Chemistry
Analogues
Related compounds include 1B-LSD, 1DD-LSD, 1P-LSD, 1V-LSD, ALD-52, 1cP-AL-LAD, AL-LAD, ETH-LAD, 1P-ETH-LAD, PRO-LAD, LSM-775, and LSZ, among others.History
1cP-LSD was first synthesized as a legal LSD alternative by Lizard Labs, a Netherlands based research chemical laboratory.Society and culture
1cP-LSD is not a controlled substance in Canada as of 2025.Sweden
suggested classifying 1cP-LSD as a dangerous substance on 18 December 2019 and later classified it as such on 22 April 2021.1cP-LSD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.Research
1cP-LSD has been investigated as a potential treatment for anxiety in dogs and cats.